Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;57(2):176-82.

Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012

Mary Kay Blake  1 , Brittany J Carr  1 , Glenna E Mauldin  1
Affiliations

Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012

Mary Kay Blake et al. Can Vet J. 2016 Feb.

Abstract
in English, French

Clinically significant hypersensitivity reactions (HSRs) to the chemotherapy drug L-asparaginase are reported in humans and dogs, but frequency in small animals is not well-defined. This study retrospectively evaluated the frequency of HSR to L-asparaginase given by IM injection to dogs and cats with lymphoid malignancies. The medical records of all dogs and cats treated with at least 1 dose of L-asparaginase chemotherapy over a 5-year period were reviewed. A total of 370 doses of L-asparaginase were administered to the dogs, with 88 of 142 dogs receiving multiple doses, and 6 dogs experiencing an HSR. A total of 197 doses were administered to the cats, with 33 of 68 cats receiving multiple doses, and no cats experiencing an HSR. Hypersensitivity reactions were documented in 4.2% of dogs, and in association with 1.6% of L-asparaginase doses administered. These results show that HSRs occur uncommonly among dogs and cats, even with repeated dosing.

Réactions d’hypersensibilité associées à l’administration de L-asparaginase chez 142 chiens et 68 chats atteints de tumeurs malignes lymphoïdes: 2007–2012. Des réactions d’hypersensibilité cliniquement significatives (HCS) au médicament de chimiothérapie L-asparaginase sont signalées chez les humains et les chiens, mais leur fréquence chez les petits animaux n’est pas bien définie. Cette étude a évalué rétrospectivement la fréquence des HCS au médicament L-asparaginase administré par injection IM aux chiens et aux chats atteints de tumeurs malignes lymphoïdes. On a examiné les dossiers médicaux de tous les chiens et chats traités avec au moins une dose de chimiothérapie au médicament L-asparaginase pendant une période de 5 ans. Un total de 370 doses de L-asparaginase a été administré aux chiens, 88 des 142 chiens ont reçu des doses multiples et 6 chiens ont manifesté des HCS. Un total de 197 doses ont été administrées aux chats, 33 des 68 chats ont reçu des doses multiples et aucun chat n’a manifesté des HCS. Les HCS ont été documentées chez 4,2 % des chiens et en association avec 1,6 % des doses de L-asparaginase administrées. Ces résultats indiquent que les HCS se produisent rarement chez les chiens et les chats, même avec des doses répétées.(Traduit par Isabelle Vallières).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage of dogs i) previously prescribed prednisone and currently on prednisone at the time of L-asparaginase administration (previous), ii) prescribed prednisone at the time of L-asparaginase administration (prescribed), or iii) not on concurrent prednisone at the time of L-asparaginase administration (none), n = 142 dogs.
Figure 2
Figure 2
Percentage of cats i) previously prescribed corticosteroids and currently on corticosteroids at the time of L-asparaginase administration (previous), ii) prescribed corticosteroids at the time of L-asparaginase administration (prescribed), or iii) not on concurrent corticosteroids at the time of L-asparaginase administration (none), n = 68 cats.
See this image and copyright information in PMC

References

    1. Avramis VI, Panosyan EH. Pharmocokinectic/pharmacodynamic relationships of asparaginase formulations. Clin Pharmacokinet. 2005;44:367–393. - PubMed
    1. Chabner BA, Sallan SE. L-asparaginase. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. 4th ed. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins; 2006. pp. 476–483.
    1. Raetz EA, Salzer WL. Tolerabilty and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554–563. - PubMed
    1. Matus R, Leifer C, MacEwen EG. Acute lymphoblastic leukemia in the dog: A review of 30 cases. J Am Vet Med Assoc. 1983;183:859–862. - PubMed
    1. Matus RE. Chemotherapy of lymphoma and leukemia. In: Kirk RW, Bonagura JD, editors. Kirk’s Current Veterinary Therapy X. Philadelphia, Pennsylvania: WB Saunders; 1989. pp. 482–488.

Supplementary concepts